Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Balstilimab + Zalifrelimab |
Indication/Tumor Type | cervical cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | cervical cancer | predicted - sensitive | Balstilimab + Zalifrelimab | Phase II | Actionable | In a Phase II study, a combination of Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) resulted in an objective response rate of 32.8% (22/67) in patients with recurrent and/or metastatic cervical cancer positive for CD274 (PD-L1) (PMID: 34932394; NCT03495882). | 34932394 |
PubMed Id | Reference Title | Details |
---|---|---|
(34932394) | Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. | Full reference... |